TNFRSF17 and Miyoshi myopathy: In August 2022, the European Medicines Agency (EMA) granted approval for teclistamab, a BsAb targeting B-cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3) on T cells (7), for treating relapsed or refractory MM (RRMM) patients undergoing at least three prior therapeutic regimens (8).